Oryzon announces voting results from its 2024 annual general meeting of shareholders

Madrid and cambridge, mass., june 28, 2024 (globe newswire) -- oryzon genomics, s.a. (isin code: es0167733015, ory), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, announced the voting results from its annual general meeting of shareholders held today in madrid. a total of 27,110,751 of the issued and outstanding common shares of the corporation (representing 42.6867% of the capital stock) were represented either in person or by proxy at the meeting.
GM Ratings Summary
Quant
GM Quant Ranking
Sector
Industry
Quant Rating
Quant Score